Foghorn Therapeutics Inc. — Earnings Quality Grade C
FHTX · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Revenue 36.8%, CFFO 14.2%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -94.5% vs revenue 36.8%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 1.16. Profits backed by cash
FCF is negative ($-0.1B)
Accruals ratio = 6.0%. Elevated
Cash $0.2B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.5x. Healthy
Other assets 12.8% vs revenue 36.8%. Normal
Write-offs up 147% YoY
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor FHTX continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25